AxoGen, Inc. to Report Second Quarter Financial Results and Host Conference Call on Wednesday, August 3, 2016
July 20 2016 - 7:00AM
AxoGen, Inc. (NASDAQ:AXGN), a leader in developing and marketing
innovative surgical solutions for peripheral nerve injuries, today
announced that it will report second quarter financial results on
Wednesday, August 3, 2016 after the market closes. AxoGen
management will host an investment-community conference call and
web cast following the release at 4:30PM ET to discuss the
financial results and provide a corporate update.
Investors interested in participating in the
conference call by phone may do so by dialing toll free at (877)
407-0993, or use the direct dial-in number at (201) 689-8795.
Those interested in listening to the conference call live via
the Internet may do so by visiting
www.axogeninc.equisolvewebcast.com/q2-2016.
Following the conference call, a replay will be
available on the company's website at www.axogeninc.com, under
‘investors’.
About AxoGen AxoGen (AXGN) is a
leading medical technology company dedicated to peripheral nerve
repair. AxoGen's portfolio of regenerative medicine products is
available in the United States, Canada and several other countries
and includes Avance® Nerve Graft, an off-the-shelf processed human
nerve allograft for bridging severed nerves without the
comorbidities associated with a second surgical site, AxoGuard®
Nerve Connector, a porcine submucosa extracellular matrix ("ECM")
coaptation aid for tensionless repair of severed nerves, and
AxoGuard® Nerve Protector, a porcine submucosa ECM product used to
wrap and protect injured peripheral nerves and reinforce the nerve
reconstruction while preventing soft tissue attachments. Along with
these core surgical products, AxoGen also offers AxoTouchTM
Two-Point Discriminator and AcroValTM Neurosensory & Motor
Testing System. These evaluation and measurement tools assist
healthcare professionals in detecting changes in sensation,
assessing return of sensory, grip and pinch function, evaluating
effective treatment interventions, and providing feedback to
patients on nerve function.
Cautionary Statements Concerning Forward-Looking
StatementsThis Press Release contains "forward-looking" statements
as defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on management's current expectations or
predictions of future conditions, events or results based on
various assumptions and management's estimates of trends and
economic factors in the markets in which we are active, as well as
our business plans. Words such as "expects", "anticipates",
"intends", "plans", "believes", "seeks", "estimates", "projects",
"forecasts", "continue", "may", "should", "will" variations of such
words and similar expressions are intended to identify such
forward-looking statements. The forward-looking statements may
include, without limitation, statements regarding our growth, our
2016 guidance, product development, product potential, financial
performance, sales growth, product adoption, market awareness of
our products, data validation, our visibility at and sponsorship of
conferences and educational events. The forward-looking statements
are subject to risks and uncertainties, which may cause results to
differ materially from those set forth in the statements.
Forward-looking statements in this release should be evaluated
together with the many uncertainties that affect AxoGen's business
and its market, particularly those discussed in the risk factors
and cautionary statements in AxoGen's filings with the Securities
and Exchange Commission. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those projected. The forward-looking statements are
representative only as of the date they are made, and, except as
required by law, AxoGen assumes no responsibility to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts:
AxoGen, Inc.
Peter J. Mariani, Chief Financial Officer
InvestorRelations@AxoGenInc.com
The Trout Group – Investor Relations
Brian Korb
646.378.2923
bkorb@troutgroup.com
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Axogen (NASDAQ:AXGN)
Historical Stock Chart
From Apr 2023 to Apr 2024